Women's Health News

RSS

Genta presents tesetaxel dose-ranging trial results at ASCO 2010

Genta Incorporated announced today the presentation of results from two dose-ranging trials of tesetaxel, the Company's novel oral tubulin inhibitor. Results showed potential activity in patients with taxane-resistant cancers, along with no evidence of hypersensitivity and a low incidence of nerve damage, both of which are common side effects of standard taxanes.

8 Jun 2010

Evidence-based oral health guidelines for pregnant women

Health care providers now have evidence-based guidelines to emphasize the importance of pregnant women maintaining good oral health care and the safety of providing appropriate treatment during pregnancy as published in the June Journal of the California Dental Association.

8 Jun 2010

Women who quit smoking during pregnancy will prevent infant deaths

If more women quit smoking before they became pregnant, it would save infant lives, concludes a new study from the Centers for Disease Control and Prevention (CDC).

8 Jun 2010

Opinions: Improving maternal health

"Delivering A Better Future For Women and Girls," East African (Manguyu, 6/7).

8 Jun 2010

UNFPA, CARE partner to improve health of women and girls

Leaders from UNFPA, United Nations Population Fund, and CARE International announced today at the Women Deliver Conference an agreement to enhance collaboration on maternal health programs in more than 25 countries. This unique collaboration will bring together UNFPA's effective work with national governments and CARE's expertise in engaging local communities.

8 Jun 2010

Chronix' DNA blood tests detect prostate, breast cancer with 92% sensitivity and 100% specificity

Chronix Biomedical today reported new data further demonstrating that its DNA blood tests have the potential to accurately detect early stage breast and prostate cancers. Chronix's proprietary technology identifies disease-specific genetic fingerprints based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells.

8 Jun 2010

Gates Foundation to invest $1.5 billion for integrated women's and children's health programs

Melinda Gates today urged global leaders to make women's and children's health a top priority, and announced that the Gates Foundation will invest $1.5 billion over the next five years to support maternal and child health, family planning, and nutrition programs in developing countries.

8 Jun 2010

Erlotinib can reduce lung cancer death by 26% : Study

Three times as many women with advanced lung cancer were alive and had no progression of their cancer 12 months after taking the drug erlotinib (also known as Tarceva) compared to those who did not receive the drug according to new data being presented at the ASCO1 conference today (Monday).

8 Jun 2010

G8 final communique draft shows agreement on maternal, child health initiative, funding amounts not yet set

A final communique draft completed last month for the upcoming G8 summit states that leaders will agree on a maternal health initiative that focuses on improving access to sexual and reproductive health services, including family planning, in the developing world, the Globe and Mail reports. The draft leaves "G8 countries free to decide whether their programs on reproductive health will fund abortions" (Clark, 6/4).

8 Jun 2010

U.N. Secretary-General, Sec. of State Clinton address Women Deliver conference

Governments worldwide should work with the U.N. on a joint action plan to significantly improve the health of women and children around the world by 2015, U.N. Secretary-General Ban Ki-moon said in a speech at the opening of the Women Deliver conference on Monday in Washington, DC, Agence France-Presse reports.

8 Jun 2010

30 percent of Aussie mums think it’s OK to drink alcohol while pregnant

A new Australian study has revealed an alarming trend showing one in three pregnant or breastfeeding woman are still drinking alcohol. The Alcohol Education and Rehabilitation Foundation (AERF) feel that in spite of warnings to pregnant women to cut out alcohol completely from their diets, many women are ignoring such warnings.

7 Jun 2010

Lawsuit to be launched over breast cancer gene patent

BRCA1 and BRCA2 are two genes that have been identified to hold a key to women’s susceptibility to get breast or ovarian cancer. Changes also known as mutations in these genes are significant in women who go on to develop breast or ovarian cancer. Melbourne-based company Genetic Technologies Limited (GTL) has the exclusive license from American biotechnology company Myriad Genetics to carry out testing for the genes in Australia. Myriad holds a patent for these genes.

7 Jun 2010

The Female Health Company granted U.S. Patent for FC2 Female Condom

The Female Health Company today announced that on June 1, 2010, the U.S. Patent office issued patent number U.S. 7,726,316 B1 for its second generation product, the FC2 Female Condom. In addition to the newly issued U.S. patent, Spain, Greece and Turkey recently issued patents on the FC2 Female Condom.

7 Jun 2010

Chronix's serum DNA assays have potential to detect early stage breast cancer, prostate cancer

Chronix Biomedical today reported new data further demonstrating that its serum DNA blood tests have the potential to accurately detect early stage breast cancer and prostate cancer. Chronix's proprietary technology identifies disease-specific genetic fingerprints based on circulating DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells.

7 Jun 2010

Aeterna Zentaris presents positive data from AEZS-108 Phase 2 study in ovarian cancer at ASCO 2010

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it presented positive efficacy and safety data for its doxorubicin targeted conjugate compound, AEZS-108, in ovarian cancer.

7 Jun 2010

Clinical trial data of imetelstat in patients with breast cancer presented at ASCO annual meeting

Geron Corporation today announced the presentation of data from the clinical trial of imetelstat (GRN163L), the company's telomerase inhibitor drug, in combination with paclitaxel and bevacizumab in patients with breast cancer at the 2010 American Society of Clinical Oncology annual meeting in Chicago.

7 Jun 2010

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study of Avastin (bevacizumab) that showed women with previously untreated advanced ovarian cancer who received Avastin in combination with chemotherapy, followed by the continuation of Avastin alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening (progression-free survival or PFS) compared to chemotherapy alone.

7 Jun 2010

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Amgen today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology Annual Meeting.

7 Jun 2010

Bevacizumab extends progression-free survival in women with advanced ovarian cancer

Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards significantly extends progression-free survival. Women receiving the new treatment regimen saw no worsening of their disease for 14.1 months, compared to 10.3 months for women receiving standard therapy.

7 Jun 2010

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Results of a Phase III study presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's eribulin mesylate significantly improved median overall survival (OS) compared with Treatment of Physician's Choice (TPC) in heavily pre-treated metastatic breast cancer patients.

7 Jun 2010

Women's Health News

Genta presents tesetaxel dose-ranging trial results at ASCO 2010

Evidence-based oral health guidelines for pregnant women

Women who quit smoking during pregnancy will prevent infant deaths

Opinions: Improving maternal health

UNFPA, CARE partner to improve health of women and girls

Chronix' DNA blood tests detect prostate, breast cancer with 92% sensitivity and 100% specificity

Gates Foundation to invest $1.5 billion for integrated women's and children's health programs

Erlotinib can reduce lung cancer death by 26% : Study

G8 final communique draft shows agreement on maternal, child health initiative, funding amounts not yet set

U.N. Secretary-General, Sec. of State Clinton address Women Deliver conference

30 percent of Aussie mums think it’s OK to drink alcohol while pregnant

Lawsuit to be launched over breast cancer gene patent

The Female Health Company granted U.S. Patent for FC2 Female Condom

Chronix's serum DNA assays have potential to detect early stage breast cancer, prostate cancer

Aeterna Zentaris presents positive data from AEZS-108 Phase 2 study in ovarian cancer at ASCO 2010

Clinical trial data of imetelstat in patients with breast cancer presented at ASCO annual meeting

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Bevacizumab extends progression-free survival in women with advanced ovarian cancer

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News